A detailed history of Octagon Capital Advisors LP transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 10,000,000 shares of UNCY stock, worth $5.6 Million. This represents 1.76% of its overall portfolio holdings.

Number of Shares
10,000,000
Previous 8,559,000 16.84%
Holding current value
$5.6 Million
Previous $3.51 Million 125.14%
% of portfolio
1.76%
Previous 0.85%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.35 - $0.81 $504,349 - $1.17 Million
1,441,000 Added 16.84%
10,000,000 $7.9 Million
Q3 2024

Nov 14, 2024

BUY
$0.24 - $0.54 $2.05 Million - $4.62 Million
8,559,000 New
8,559,000 $3.51 Million

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $8.43M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.